J Rheum Dis 2012; 19(2): 67-72
Published online April 30, 2012
© Korean College of Rheumatology
서창희
아주대학교 의과대학 류마티스내과학교실
B cells play an important role in the pathogenesis of autoimmune disease. B cells not only produce pathogenic autoantibodies, but also present self-antigens to T cells and provide costimulatory signals for self-reactiveT cells. Recently, biologics have been tried in several autoimmune diseases as immune modulators with some promising results. Among them, several biologic agents that target B cells have led to improved patients' outcomes and quality of life in patients with rheumatoid arthritis and systemic lupus erythematosus. These agents either deplete B cells by targeting B cell surface antigens, such as CD20 and CD22, or block B cell survival by inhibiting the activity of B cell survival factors, such as BLyS and APRIL. Initially, I discuss briefly the role of B cells in driving autoimmune diseases, and then focus on the efficacy and safety data of the B cell-targeted therapy in rheumatoid arthritis and systemic lupus erythematosus.
Keywords B cell, Target, Treatment, Rheumatoid arthritis, Lupus
J Rheum Dis 2012; 19(2): 67-72
Published online April 30, 2012
Copyright © Korean College of Rheumatology.
서창희
아주대학교 의과대학 류마티스내과학교실
Chang-Hee Suh
Department of Rheumatology, Ajou University School of Medicine, Suwon, Korea
Correspondence to:Chang-Hee Suh
B cells play an important role in the pathogenesis of autoimmune disease. B cells not only produce pathogenic autoantibodies, but also present self-antigens to T cells and provide costimulatory signals for self-reactiveT cells. Recently, biologics have been tried in several autoimmune diseases as immune modulators with some promising results. Among them, several biologic agents that target B cells have led to improved patients' outcomes and quality of life in patients with rheumatoid arthritis and systemic lupus erythematosus. These agents either deplete B cells by targeting B cell surface antigens, such as CD20 and CD22, or block B cell survival by inhibiting the activity of B cell survival factors, such as BLyS and APRIL. Initially, I discuss briefly the role of B cells in driving autoimmune diseases, and then focus on the efficacy and safety data of the B cell-targeted therapy in rheumatoid arthritis and systemic lupus erythematosus.
Keywords: B cell, Target, Treatment, Rheumatoid arthritis, Lupus
Kichul Shin, Hyeongap Jang, Won Mo Jang, Jin-Seok Lee, Yeong-Wook Song
J Rheum Dis 2013; 20(1): 24-29Jung-Soo Song, M.D., Ph.D.
The Journal of the Korean Rheumatism Association 2007; 14(1): 1-14Byeongzu Ghang, M.D., Ph.D., Jin Kyun Park, M.D., Ph.D., Ji Hyeon Ju, M.D., Ph.D., Seungwoo Han, M.D., Ph.D.
J Rheum Dis -0001; ():